Diet aid or aid to die: an update on 2,4-dinitrophenol (2,4-DNP) use as a weight-loss product.
Daniela SousaHelena CarmoRita Roque BravoFélix CarvalhoMaria de Lourdes BastosPaula Guedes de PinhoDiana Dias-da-SilvaPublished in: Archives of toxicology (2020)
During the last decades, we have witnessed unparalleled changes in human eating habits and lifestyle, intensely influenced by cultural and social pressures. Sports practice became strongly implemented in daily routines, and visits to the gym peaked, driven by the indulgence in intensive 'weight-loss programs'. The pledge of boasting a healthy and beautiful body instigates the use of very attractive 'fat burners', which are purportedly advertised as safe products, easily available in the market and expected to quickly reduce body weight. In this context, the slimming properties of 2,4-dinitrophenol (2,4-DNP) galvanised its use as a weight-loss product, despite the drug ban for human consumption in many countries since 1938, due to its adverse effects. The main symptoms associated with 2,4-DNP intoxication, including hyperthermia, tachycardia, decreased blood pressure, and acute renal failure, motivated a worldwide warning, issued by the Interpol Anti-Doping Unit in 2015, reinforcing its hazard. Information on the effects of 2,4-DNP mainly derive from the intoxication cases reported by emergency care units, for which there is no specific antidote or treatment. This review provides a comprehensive update on 2,4-DNP use, legislation and epidemiology, chemistry and analytical methodologies for drug determination in commercial products and biological samples, pharmacokinetics and pharmacodynamics, toxicological effects, and intoxication diagnosis and management.
Keyphrases
- weight loss
- bariatric surgery
- healthcare
- roux en y gastric bypass
- body weight
- endothelial cells
- gastric bypass
- blood pressure
- public health
- glycemic control
- physical activity
- drug induced
- emergency department
- obese patients
- primary care
- pluripotent stem cells
- weight gain
- quality improvement
- risk factors
- mental health
- health insurance
- liver failure
- depressive symptoms
- intensive care unit
- social media
- sleep quality
- adverse drug
- fatty acid
- high resolution
- combination therapy
- liquid chromatography
- respiratory failure
- acute respiratory distress syndrome